A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

A Randomized, Double-blind, Dose-escalating, Placebo-controlled Phase Ib Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

This is a randomized, double-blind, dose-escalating, placebo-controlled phase Ib clinical study.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: VC005 tablets; Drug: VC005 Tablets Placebo

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Xiaojuan Lai; Phone Number: 15358160458; Email: lai_xiaojuan@vcarepharmatech.com

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130061
      • The First Bethune Hospital Of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The subject or his/her guardian understands and voluntarily signs the informed consent form (ICF);
2. The age at the time of signing the ICF is between 18 and 70 years (including borderline values), regardless of gender;
3. A body mass index [BMI = weight (kg)/height 2 (m2)] of 18 ~30 kg/m2 at the time of screening;
4. Rheumatoid arthritis diagnosed according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 rheumatoid arthritis (RA) classification criteria and at least 3 months of disease duration at the time of the screening visit;
5. A diagnosis of moderately or severely active RA;
6. Have not used any disease-modifying antirheumatic drugs (DMARDs) prior to the first dose of the trial, or have been on a stable dose of methotrexate (MTX) for ≥4 weeks prior to the first dose, or have used methotrexate, salbutamol, or a dose of a drug such as methotrexate. (SASP), chloroquine/hydroxychloroquine, gold, penicillamine, etc., but had stopped using them for ≥3 weeks before the first dose. have stopped using the drug for ≥ 3 months;
7. Subjects who have been stable on NSAIDs prior to the first dose must have had a fixed drug class and a stable dose for ≥4 weeks and continue at a stable dose for the duration of the clinical trial;
8. Subjects who have been stable on oral glucocorticoids prior to the first dose must have been stable for ≥4 weeks at a dose of ≤10 mg/day (prednisone or equivalent dose of other glucocorticoids) and continue at a stable dose for the duration of the clinical trial;
9. The subject is able to communicate well with the investigator and is willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

1. The subjects who are allergic to the study drug or any of the components of the study drug, or are allergic (multiple drug and food allergies);

2. The subjects have used any of the following medications or treatments:

   Tyrosine kinase (JAK) inhibitor class drugs, within 1 month prior to randomization/biologic disease-modifying antirheumatic drugs (bDMARDs) within 5 half-lives prior to randomization or within 3 months,etc；

3. The subjects have a history or evidence of any of the following diseases:

   Presence of any systemic inflammatory disease other than RA (except secondary dry syndrome)/lymphoproliferative disease, etc;

4. The presence of any abnormal laboratory test at screening that meets the following criteria (not allowed to receive within 2 weeks prior to screening) Any medical support therapy such as leukocyte boosting, anemia improvement, liver protection and enzyme reduction, blood transfusion, etc;
5. Positive hepatitis B surface antigen (HBsAg) or negative hepatitis B surface antigen, negative hepatitis B surface antibody, positive hepatitis B core antibody (HBcAb) with hepatitis B virus honeybee venom(HBV)-DNA test results above the lower limit of detection; positive hepatitis C antibody (HCVAb) with hepatitis C virus ribonucleic acid (HCV-RNA) test results above the lower limit of detection; positive syphilis spirochete antibody (TPAb) ，etc;
6. Screening period ECG corrected QT interval(QTC): > 470 ms for men and > 480 ms for women, or abnormalities of clinical significance that, in the judgment of the investigator, preclude enrollment;
7. Those with a history of substance abuse or drug use within the past five years;
8. Those who have a positive urine drug screen or alcohol screen;
9. Female patients who are planning to become pregnant or who are pregnant or breastfeeding, or who are unable to use effective contraception throughout the trial and for 6 months after the trial ends;
10. Who, for any reason, are deemed by the investigator to be unsuitable for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VC005 Tablets Low Dose groups	Drug: VC005 tablets; VC005 groups repeat administration for 4 weeks
Experimental: VC005 Tablets Medium Dose groups	Drug: VC005 tablets; VC005 groups repeat administration for 4 weeks
Experimental: VC005 Tablets High Dose groups	Drug: VC005 tablets; VC005 groups repeat administration for 4 weeks
Experimental: VC005 Tablets Placebo Low Dose groups	Drug: VC005 Tablets Placebo; VC005 placebo groups repeat administration for 4 weeks
Experimental: VC005 Tablets Placebo Medium Dose groups	Drug: VC005 Tablets Placebo; VC005 placebo groups repeat administration for 4 weeks
Experimental: VC005 Tablets Placebo High Dose groups	Drug: VC005 Tablets Placebo; VC005 placebo groups repeat administration for 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Peak time in plasma(Tmax)	Day1、Day8、Day15、Day22、Day28
Peak Plasma Concentration (Cmax）	Day1、Day8、Day15、Day22、Day28

Collaborators and Investigators

• Sponsor: Jiangsu vcare pharmaceutical technology co., LTD
• Investigators: Principal Investigator: Yanhua Ding, The First Hospital of Jilin University; Principal Investigator: Nanya Wang, The First Hospital of Jilin University

Study record dates

Study Major Dates

• Study Start (Actual): June 12, 2023
• Primary Completion (Actual): October 18, 2023
• Study Completion (Actual): October 25, 2023

Study Registration Dates

• First Submitted: May 5, 2023
• First Submitted That Met QC Criteria: May 24, 2023
• First Posted (Actual): May 25, 2023

Study Record Updates

• Last Update Posted (Estimated): November 3, 2023
• Last Update Submitted That Met QC Criteria: November 1, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: VC005-103

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No